Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini, Cairo, 11562, Egypt.
AAPS PharmSciTech. 2023 Feb 14;24(2):66. doi: 10.1208/s12249-023-02516-9.
The human eye is a sophisticated organ with distinctive anatomy and physiology that hinders the passage of drugs into targeted ophthalmic sites. Effective topical administration is an interest of scientists for many decades. Their difficult mission is to prolong drug residence time and guarantee an appropriate ocular permeation. Several ocular obstacles oppose effective drug delivery such as precorneal, corneal, and blood-corneal barriers. Routes for ocular delivery include topical, intravitreal, intraocular, juxtascleral, subconjunctival, intracameral, and retrobulbar. More than 95% of marketed products exists in liquid state. However, other products could be in semi-solid (ointments and gels), solid state (powder, insert and lens), or mixed (in situ gel). Nowadays, attractiveness to nanotechnology-based carries is resulted from their capabilities to entrap both hydrophilic and lipophilic drugs, enhance ocular permeability, sustain residence time, improve drug stability, and augment bioavailability. Different in vitro, ex vivo, and in vivo characterization approaches help to predict the outcomes of the constructed nanocarriers. This review aims to clarify anatomy of the eye, various ocular diseases, and obstacles to ocular delivery. Moreover, it studies the advantages and drawbacks of different ocular routes of administration and dosage forms. This review also discusses different nanostructured platforms and their characterization approaches. Strategies to enhance ocular bioavailability are also explained. Finally, recent advances in ocular delivery are described.
人眼是一个结构复杂、功能独特的器官,这阻碍了药物进入眼部靶位。将药物有效递送至眼部是科学家们几十年来的研究兴趣。他们的艰巨任务是延长药物在眼部的停留时间并保证适当的眼内渗透。几种眼部障碍阻碍了有效的药物传递,如眼前部、角膜和血眼屏障。眼部给药途径包括局部给药、玻璃体内给药、眼内给药、巩膜下给药、结膜下给药、前房内给药和球后给药。超过 95%的上市产品以液体状态存在。然而,其他产品可以是半固体(眼膏和凝胶)、固体(粉末、插入物和镜片)或混合(原位凝胶)。如今,基于纳米技术的载体之所以具有吸引力,是因为它们能够同时包封亲水性和疏水性药物,增加眼内通透性,延长滞留时间,提高药物稳定性,并增加生物利用度。不同的体外、离体和体内特性评估方法有助于预测所构建的纳米载体的结果。本综述旨在阐明眼部解剖结构、各种眼部疾病以及眼部递药的障碍。此外,它还研究了不同眼部给药途径和剂型的优缺点。本文还讨论了不同的纳米结构平台及其特性评估方法。还解释了提高眼部生物利用度的策略。最后,描述了眼部给药的最新进展。